Since the involvement of the Akt/mTOR pathway and its associated effector proteins have been reported to be linked to the pathogenesis of SSc, targeting inflammation and the Akt/mTOR and associated pathways is a promising approach in treating patients with this skin condition [159]. This evidence concerns the gene AKT1 and systemic sclerosis.